Is True Non-Secretion of Chromogranin A an Unfavorable Prognostic Factor in Patients with ENETs TNM Stage IV Gastroenteropancreatic Neuroendocrine Tumors? Abstract #1543

Introduction: Chromogranin A (CgA) is the best available serum marker for the work-up of gastroenteropancreatic NETs (GEP-NETs) and correlates with tumor volume & biological activity. During diagnosis & follow-up we found patients with elevated CgA levels and patients without elevated CgA levels (=‘true non-secretors’). We postulated that lack of secretion is a sign of dedifferentiation with a poorer prognosis.
Aim(s): To determine whether true non-secretion of CgA is an unfavorable prognostic factor in patients with ENETs TNM Stage IV GEP-NETs.
Materials and methods: Patients using PPIs & MEN-1 patients were excluded. Baseline & follow-up CgA were measured in a large single-center cohort with one assay (IRMA). Cut-off values for baseline & follow-up CgA: normal (reference range (RR)), intermediate (≤ 2x upper limit of normal (ULN)), high (2-10x ULN) and very high (>10x ULN). Overall survival (OS) was estimated using Kaplan–Meier methods & hazard ratios with a Cox proportional hazards model.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Biomarkers
Presenting Author: drs. Kimberly Kamp
Keywords: GEP-NET, CgA, prognosis

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1563 Impact of Early Surgery on Prognosis in Advanced Gastro-entero-pancreatic Neuroendocrine Tumours (GEP-NET)
Introduction: In gastro-entero-pancreatic neuroendocrine tumours (GEP-NET) the role of surgery remains to be determined.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Surgical treatment
Presenting Author: MD Patrizia Kump
#305 Risk Stratification Using Octreotide Test for Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results of Prospective Validation of the Test
Introduction: We recently demonstrated that a plasma CgA decrement >30% after octreotide s.c. injection is a simple criterion for treatment with Somatostatin analogues (SSA) of gastroenteropancreatic endocrine tumors.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Sara Massironi
#2079 Excellent Survival Outcomes for NET Patients Treated within NETwerk, a Collaborative ENETS Center of Excellence
Introduction: Since 2016, patients with neuroendocrine tumors (NETs) of 9 hospitals in Belgium, are jointly discussed during multidisciplinary tumor boards (NET MDT) within NETwerk, a ENETS Center of Excellence.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Prof. Marc Peeters
#1142 GastroEnteroPancreatic and Thoracic Neuroendocrine Tumors and the Ectopic Adrenocorticotropin Syndrome
Introduction: Ectopic Adrenocorticotropin (ACTH) Syndrome (EAS) is associated with a variety of malignancies, predominantly of neuroendocrine origin. Several series report on the relative contribution of EAS in the spectrum of Cushing’s syndrome. However, information on the incidence/prevalence and prognosis of EAS in the setting of patients diagnosed with Thoracic or GEP-NETs is virtually absent.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: drs. Kimberly Kamp
#418 Chromogranin A (CgA) in the Diagnosis and Monitoring of Patients with Gastroenteropancreatic (GEP) Neuroendocrine Tumors (NET): A Single-Institution Experience
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP NET) are heterogeneous neoplasms with different malignancy. Plasma chromogranin A (CgA) may play an important role in predicting outcome.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Sara Massironi
Keywords: CgA, GEP-NET